
Christopher J Cheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11645797/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleases. Nature Communications, 2021, 12, 4219.	5.8	29
2	miR-155 drives oncogenesis by promoting and cooperating with mutations in the c-Kit oncogene. Oncogene, 2019, 38, 2151-2161.	2.6	21
3	Exercise and weight loss interventions and miRNA expression in women with breast cancer. Breast Cancer Research and Treatment, 2018, 170, 55-67.	1.1	25
4	Leveraging Rational Protein Engineering to Improve mRNA Therapeutics. Nucleic Acid Therapeutics, 2018, 28, 74-85.	2.0	8
5	A "top-down―approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery. Biomaterials, 2018, 176, 122-130.	5.7	49
6	In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery. Nature Communications, 2016, 7, 13304.	5.8	143
7	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 927-939.	0.4	128
8	A holistic approach to targeting disease with polymeric nanoparticles. Nature Reviews Drug Discovery, 2015, 14, 239-247.	21.5	373
9	miR-155 Is Essential for Inflammation-Induced Hippocampal Neurogenic Dysfunction. Journal of Neuroscience, 2015, 35, 9764-9781.	1.7	83
10	Systemic delivery of blood–brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue. Journal of Drug Targeting, 2015, 23, 736-749.	2.1	73
11	Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6597-605.	3.3	11
12	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature, 2015, 518, 107-110.	13.7	709
13	Sustained delivery of proangiogenic microRNAâ€132 by nanoparticle transfection improves endothelial cell transplantation. FASEB Journal, 2014, 28, 908-922.	0.2	72
14	Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3062-71.	3.3	31
15	Regeneration of mammalian cochlear and vestibular hair cells through Hes1/Hes5 modulation with siRNA. Hearing Research, 2013, 304, 91-110.	0.9	34
16	Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 1124-1134.	1.7	51
17	Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics. Current Medicinal Chemistry, 2013, 20, 3582-3593.	1.2	48
18	A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery Journal of Clinical Oncology, 2013, 31, e15543-e15543.	0.8	0

#	Article	IF	CITATIONS
19	The Duality of OncomiR Addiction in the Maintenance and Treatment of Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 232-237.	1.0	48
20	Surface modified poly(β amino ester)-containing nanoparticles for plasmid DNA delivery. Journal of Controlled Release, 2012, 164, 41-48.	4.8	75
21	Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nature Materials, 2012, 11, 82-90.	13.3	360
22	Polymer Nanoparticle-Mediated Delivery of MicroRNA Inhibition and Alternative Splicing. Molecular Pharmaceutics, 2012, 9, 1481-1488.	2.3	84
23	Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1695-704.	3.3	439
24	Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials, 2011, 32, 6194-6203.	5.7	106